Over the last two decades, there have been many studies on children who have sought an effective and safe treatment to eradicate Helicobacter pylori infection, but as yet, no therapy regimen has been found which is always effective and safe. Differences in drug response among pediatric patients are common. Such individual variability in drug response is multifactorial, including environmental, genetic, development and disease determinants that affect the disposition of a given drug. In pediatric efficacy studies for the management of H. pylori eradication in children, the most commonly tested regimen has contained a combination of proton pump inhibitor (PPI), clarithromycin and amoxicillin, followed by triple therapies containing PPI, clarithromycin and nitroimidazoles. Thus, PPIs are an integral part of triple therapy for H. pylori eradication in children with gastroduodenal disease. In this article, we comprehensively review, from a pediatric point of view, the literature on the clinical, pharmacologic and microbiologic properties of PPIs. We also discuss genetic, developmental and other host-related factors that may affect the efficacy of these drugs. Finally, we provide some guidance regarding their potential role and limitations for H. pylori eradication in children.

Keywords:
Drug safety, Proton pump inhibitors, Helicobacter pylori, Children, Pharmacogenomics, Developmental pharmacology
1.
Sherman PM: Appropriate strategies for testing and treating Helicobacter pylori in children: when and how? Am J Med 2004;117(suppl):S30–S35.
2.
Suerbaum S, Michetti P: Helicobacter pylori infection. N Engl J Med 2002;347:1175–1186.
3.
Pacifico L, Anania C, Osborn JF, Ferraro F, Chiesa C: Consequences of Helicobacter pylori infection in children. World J Gastroenterol 2010;16:5181–5194.
4.
Chiesa C, Pacifico L, Anania C, Poggiogalle E, Chiarelli F, Osborn JF: Helicobacter pylori therapy in children: overview and challenges. Int J Immunopathol Pharmacol 2010;23:405–416.
5.
Astrand B: Avoiding drug-drug interactions. Chemotherapy 2009;55:215–220.
6.
Suerbaum S, Leying H, Klemm K, Opferkuch W: Antibacterial activity of pantoprazole and omeprazole against Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1991;10:92–93.
7.
Soto A, García A, González CL: In vitro antagonism of rabeprazole and metronidazole upon clinical isolates of Helicobacter pylori. Chemotherapy 2009;55:308–311.
8.
Weil J, Bell GD, Powell K, Morden A, Harrison G, Gant PW, Jones PH, Trowell JE: Omeprazole and Helicobacter pylori: temporary suppression rather than true eradication. Aliment Pharmacol Ther 1991;5:309–313.
9.
Kilbridge PM, Dahms BB, Czinn SJ: Campylobacter pylori-associated gastritis and peptic ulcer disease in children. Am J Dis Child 1988;142:1149–1152.
10.
Sherman P, Shames B, Loo V, Matlow A, Drumm B, Penner J: Omeprazole therapy for Helicobacter pylori infection. Scand J Gastroenterol 1992;27:1018–1022.
11.
McNulty CA, Dent JC, Ford GA, Wilkinson SP: Inhibitory antimicrobial concentrations against Campylobacter pylori in gastric mucosa. J Antimicrob Chemother 1988;22:729–738.
12.
Westblom TU, Duriex DE: Pharmacokinetics of cefuroxime and ciprofloxacin in gastric mucosa: comparison to in vitro inhibitory concentrations against Helicobacter pylori. Microbiologica 1991;14:37–43.
13.
Qasim A, O’Morain CA, O’Connor HJ: Helicobacter pylori eradication: role of individual therapy constituents and therapy duration. Fundam Clin Pharmacol 2009;23:43–52.
14.
DeVault KR, Talley NJ: Insights into the future of gastric acid suppression. Nat Rev Gastroenterol Hepatol 2009;6:524–532.
15.
van Zanten SV, Thompson K: Should the presence of polymorphisms of CYP2C19 enzymes influence the choice of the proton pump inhibitor for treatment of Helicobacter pylori infection? Am J Gastroenterol 2006;101:1476–1478.
16.
Goddard AF, Jessa MJ, Barrett DA, Shaw PN, Idstrom JP, Cederberg C, Spiller RC: Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterology 1996;111:358–367.
17.
Goddard AF, Spiller RC: The effect of omeprazole on gastric juice viscosity, pH and bacterial counts. Aliment Pharmacol Ther 1996;10:105–109.
18.
Vandenplas Y, Rudolph C, Di Lorenzo C, Hassall E, Liptak G, Mazur L, Sondheimer J, Staiano A, Thomson M, Veereman-Wauters G, Wenzl TG: Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr 2009;49:498–547.
19.
Kato S, Takeyama J, Ebina K, Naganuma H: Omeprazole-based dual and triple regimens for Helicobacter pylori eradication in children. Pediatrics 1997;100:e3.
20.
Kato S, Ritsuno H, Ohnuma K, Linuma K, Sugiyama T, Asaka M: Safety and efficacy of one-week triple therapy for eradicating Helicobacter pylori in children. Helicobacter 1998;3:278–282.
21.
Kalach N, Raymond J, Benhamou PH, Bergeret M, Dupont C: Short-term treatment with amoxycillin, clarithromycin and lansoprazole during Helicobacter pylori infection in children. Clin Microbiol Infect 1999;5:235–236.
22.
Casswall TH, Alfvén G, Drapinski M, Bergström M, Dahlström KA: One-week treatment with omeprazole, clarithromycin, and metronidazole in children with Helicobacter pylori infection. J Pediatr Gastroenterol Nutr 1998;27:415–418.
23.
Kato S , Konno M, Maisawa S-I, Tajiri H, Yoshimura N, Shimizu T, Toyoda S, Nakayama Y, Iinuma K: Results of triple eradication therapy in Japanese children: a retrospective multicenter study. J Gastroenterol 2004;39:838–843.
24.
Kawakami E, Machado RS, Ogata SK, Langner M, Fukushima E, Carelli AP, Bonucci VC, Patricio FR: Furazolidone-based triple therapy for H. pylori gastritis in children. World J Gastroenterol 2006;12:5544–5549.
25.
Ozen H, Dinier G, Akyon Y, Kocak N, Yuce A, Gurakan F: Helicobacter pylori infection and recurrent abdominal pain in Turkish children. Helicobacter 2001;6:234–238.
26.
Shcherbakov PL, Filin VA, Volkov IA, Tatarinov PA, Belousov YB: A randomized comparison of triple therapy Helicobacter pylori eradication regimens in children with peptic ulcers. J Int Med Res 2001;29:147–153.
27.
Behrens R, Lang T, Keller KM, Bindl L, Becker M, Rodeck B, Küster P, Wündisch GF, Stolte M: Dual versus triple therapy of Helicobacter pylori infection: results of a multicentre trial. Arch Dis Child 1999;81:68–70.
28.
Cadranel S, Bontemps P, Van Biervliet S, Alliet P, Lauvau D, Vandenhoven G, Vandenplas Y: Improvement of the eradication rate of Helicobacter pylori gastritis in children is by adjunction of omeprazole to a dual antibiotherapy. Acta Paediatr 2007;96:82–86.
29.
Ashorn M, Rago T, Kokkonen J, Ruuska T, Rautelin H, Karikoski R: Symptomatic response to Helicobacter pylori eradication in children with recurrent abdominal pain. J Clin Gastroenterol 2004;38:646–650.
30.
Bahremand S, Nematollahi LR, Fourutan H, Tirgari F, Nouripour S, Mir E, Aghakhani S: Evaluation of triple and quadruple Helicobacter pylori eradication therapies in Iranian children: A randomized clinical trial. Eur J Gastroenterol Hepatol 2006;18:511–514.
31.
Francavilla R, Lionetti E, Castellaneta SP, Magistà AM, Boscarelli G, Piscitelli D, Amoroso A, Di Leo A, Miniello VL, Francavilla A, Cavallo L, Ierardi E: Improved efficacy of 10-day sequential treatment for Helicobacter pylori eradication in children: a randomized trial. Gastroenterology 2005;129:1414–1419.
32.
Gottrand F, Kalach N, Spyckerelle C, Guimber D, Mougenot J-F, Tounian P, Lenaerts C, Roquelaure B, Lachaux A, Morali A, Dupont C, Maurage C, Husson M-O, Barthélemy P: Omeprazole combined with amoxicillin and clarithromycin in the eradication of Helicobacter pylori in children with gastritis: a prospective randomized double-blind trial. J Pediatr 2001;139:664–668.
33.
Kocak N , Saltik IN, Ozen H, Yuce A, Gurakan F: Lansoprazole triple therapy for Turkish children with Helicobacter pylori infections. J Pediatr Gastroenterol Nutr 2001;32:614.
34.
Moshkowitz M , Reif S, Brill S, Ringel Y, Arber N, Halpern Z, Bujanover Y: One-week triple therapy with omeprazole, clarithromycin, and nitroimidazole for Helicobacter pylori infection in children and adolescents. Pediatrics 1998;102:e14.
35.
Oderda G , Marinello D, Lerro P, Ruvidi M, de’Angelis GL, Ferzetti A, Cucchiara S, Franco MT, Romano C, Strisciuglio P, Pensabene L: Dual vs. triple therapy for childhood Helicobacter pilori gastritis: a double-blind randomized multicenter trial. Helicobacter 2004;9:293–301.
36.
Shashidhar H, Peters J, Lin C-H, Rabah R, Thomas R, Tolia V: A prospective trial of lansoprazole triple therapy for pediatric Helicobacter pylori infection. J Pediatr Gastroenterol Nutr 2000;30:276–282.
37.
Tirén U, Sandstedt B, Finkel Y: Helicobacter pylori gastritis in children: efficacy of 2 weeks of treatment with clarithromycin, amoxicillin and omeprazole. Acta Paediatr 1999;88:166–168.
38.
Rudolph CD, Mazur LJ, Liptak GS, Baker RD, Boyle JT, Colletti RB, Gerson WT, Werlin SL: Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children: recommendations of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 2001;32(suppl 2):1–31.
39.
Patel AS, Pohl JF, Easley DJ: What’s new: proton pump inhibitors and pediatrics. Pediatr Rev 2003;24:12–15.
40.
Shin JM, Sachs G: Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep 2008;10:528–534.
41.
Gibbons TE, Gold BD: The use of proton pump inhibitors in children. A comprehensive review. Pediatr Drugs 2003;5:25–40.
42.
Kearns GL, Winter HS: Proton pump inhibitors in pediatrics: relevant pharmacokinetics and pharmacodynamics. J Pediatr Gastroenterol Nutr 2003;37(Suppl 1):52–59.
43.
Furuta T, Shirai N, Sugimoto M, Ohashi K, Ishizaki T: Pharmacogenomics of proton pump inhibitors. Pharmacogenomics 2004;5:181–202.
44.
Wilkinson GR: Drug metabolism and variability among patients in drug response. N Engl J Med 2005;352:2211–2221.
45.
Kearns GL, Andersson T, James LP, Gaedigk A, Kraynak RA, Abdel-Rahman SM, Ramabadran K, van den Anker JN, Pediatric Pharmacology Research Unit Network: Omeprazole disposition in children following single-dose administration. J Clin Pharmacol 2003;43:840–848.
46.
Wedlund PJ: The CYP2C19 enzyme polymorphism. Pharmacology 2006;61:174–183.
47.
Furuta T, Ohashi K, Kosuge K, Zhao XJ, Takashima M, Kimura M, Nishimoto M, Hanai H, Kaneko E, Ishizaki T: CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 1999;65:552–561.
48.
Dickson EJ, Stuart RC: Genetics of response to proton pump inhibitor therapy: clinical implications. Am J Pharmacogenomics 2003;3:303–315.
49.
Zhou SF, Liu JP, Chowbay B: Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 2009;41:89–295.
50.
Chong E, Ensom MH: Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacotherapy 2003;23:460–471.
51.
Shirai N, Furuta T, Moriyama Y, Okochi H, Kobayashi K, Takashima M, Xiao F, Kosuge K, Nakagawa K, Hanai H, Chiba K, Ohashi K, Ishizaki T: Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 2001;15:1929–1937.
52.
Furuta T, Shirai N, Xiao F, Ohashi K, Ishizaki T: Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. Clin Pharmacol Ther 2001;70:484–492.
53.
Food and Drug Administration: Medical devices: clinical chemistry and clinical toxicology devices: drug metabolizing enzyme genotyping system. Fed Regist 2005;70:11865–11867.
54.
Saito YA, Talley NJ: AJG series: molecular biology for clinicians. Am J Gastroenterol 2009;104:2583–2587.
55.
Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Sugimura H, Ohashi K, Ishizaki T, Kaneko E: Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 2001;69:158–168.
56.
Aoyama N, Tanigawara Y, Kita T, Sakai T, Shirakawa K, Shirasaka D, Kodama F, Okumura K, Kasuga M: Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers. J Gastroenterol 1999;34(suppl 11):80–83.
57.
Dojo M, Azuma T, Saito T, Ohtani M, Muramatsu A, Kuriyama M: Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan. Dig Liver Dis 2001;33:671–675.
58.
Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T, Hanai H, Kubota T, Ishizaki T, Kaneko E: Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998;129:1027–1030.
59.
Furuta T, Shirai N, Kodaira M, Sugimoto M, Nogaki A, Kuriyama S, Iwaizumi M, Yamade M, Terakawa I, Ohashi K, Ishizaki T, Hishida A: Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H.pylori. Clin Pharmacol Ther 2007;81:521–528.
60.
Furuta T, Shirai N,Takashima M, Xiao F, Hanai H , Nakagawa K, Sugimura H, Ohashi K, Ishizaki T: Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Pharmacogenetics 2001;11:341–348.
61.
Inaba T , Mizuno M, Kawai K, Yokota K, Oguma K, Miyoshi M, Take S, Okada H, Tsuji T: Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype. J Gastroenterol Hepatol 2002;17:748–753.
62.
Isomoto H, Inoue K, Furusu H, Nishiyama H, Shikuwa S, Omagari K, Mizuta Y, Murase K, Murata I, Kohno S: Lafutidine, a novel histamine H2-receptor antagonist, vs lansoprazole in combination with amoxicillin and clarithromycin for eradication of Helicobacter pylori. Helicobacter 2003;8:111–119.
63.
Kawabata H, Habu Y, Tomioka H, Kutsumi H, Kobayashi M, Oyasu K, Hayakumo T, Mizuno S, Kiyota K, Nakajima M, Kimoto K, Inokuchi H, Kawai K: Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. Aliment Pharmacol Ther 2003;17:259–264.
64.
Miki I, Aoyama N, Sakai T, Shirasaka D, Wambura CM, Maekawa S, Kuroda K, Tamura T, Kita T, Sakaeda T, Okumura K, Kasuga M: Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan. Eur J Gastroenterol Hepatol 2003;15:27–33.
65.
Miyoshi M, Mizuno M, Ishiki K, Nagahara Y, Maga T, Torigoe T, Nasu J, Okada H, Yokota K, Oguma K, Tsuji T: A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism. J Gastroenterol Hepatol 2001;16:723–728.
66.
Okudaira K, Furuta T, Shirai N, Sugimoto M, Miura S: Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19. Aliment Pharmacol Ther 2005;21:491–497.
67.
Sapone A , Vaira D , Trepidi S, Perna F, Gatta L, Tampieri A, Ricci C, Cantelli-Forti G, Miglioli M, Biagi GL, Paolini M: The clinical role of cytochrome p450 genotypes in Helicobacter pylori management. Am J Gastroenterol 2003;98:1010–1015.
68.
Sheu BS, Kao AW, Cheng HC, Hunag SF, Chen TW, Lu CC, Wu JJ: Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism. Aliment Pharmacol Ther 2005;21:283–288.
69.
Tanigawara Y, Aoyama N,Kita T, Shirakawa K, Komada F, Kasuga M, Okumura K: CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. Clin Pharmacol Ther 1999;66:528–534.
70.
Lee JH, Jung HY, Choi KD, Song HJ, Lee GH, Kim JH: The influence of CYP2C19 polymorphism on eradication of Helicobacter pylori: a prospective randomized study of lansoprazole and rabeprazole. Gut Liver 2010;4:201–206.
71.
Ozdil B, Akkiz H, Bayram S, Bekar A, Akgöllü E, Sandikçi M: Influence of CYP2C19 functional polymorphism on Helicobacter pylori eradication. Turk J Gastroenterol 2010;21:23–28.
72.
Klotz U, Schwab M, Treiber G: CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol 2004;95:2–8.
73.
Zhao F, Wang J, Yang Y, Wang X, Shi R, Xu Z, Huang Z, Zhang G: Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis. Helicobacter 2008;13:532–541.
74.
Anderson GD, Lynn AM: Optimizing pediatric dosing: a developmental pharmacologic approach. Pharmacotherapy 2009;29:680–690.
75.
Leeder JS, Kearns GL: Pharmacogenetics in pediatrics. Implications for practice. Pediatr Clin North Am 1997;44:55–77.
76.
Kearns GL , Abdel-Rahman SM, Alander SW, Blowey L , Leeder, Kauffman RE: Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med 2003;349:1157–1167.
77.
Landes BD, Petite JP, Flouvat B: Clinical pharmacokinetics of lansoprazole. Clin Pharmacokinet 1995;28:458–470.
78.
Londong W, Londong V, Cederberg C, Steffen H: Dose-response study of omeprazole on meal-stimulated gastric acid secretion and gastrin release. Gastroenterology 1983;85:1373–1378.
79.
Brummer RJ, Geerling BJ, Stockbrügger RW: Initial and chronic gastric acid inhibition by lansoprazole and omeprazole in relation to meal administration. Dig Dis Sci 1997;42:2132–2137.
80.
Thomson AB, Sinclair P, Matisko A, Rosen E, Andersson T, Olofsson B: Influence of food on the bioavailability of an enteric-coated tablet formulation of omeprazole 20 mg under repeated dose conditions. Can J Gastroenterol 1997;11:663–667.
81.
Lodato F, Azzaroli F, Turco L, Mazzella N, Buonfiglioli F, Zoli M, Mazzella G: Adverse effects of proton pump inhibitors. Best Pract Res Clin Gastroenterol 2010;24:193–201.
82.
Tolia V, Boyer K: Long-term proton pump inhibitor use in children: a retrospective review of safety. Dig Dis Sci 2008;53:385–393.
83.
Hassall E, Kerr W, El-Serag HB: Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration. J Pediatr 2007;150:262–267.
84.
Kuipers EJ, Lundell L, Klinkenberg-Knol EC, Havu N, Festen HP, Liedman B, Lamers CB, Jansen JB, Dalenback J, Snel P, Nelis GF, Meuwissen SG: Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996;334:1018–1022.
85.
Lundell L, Havu N, Miettinen P, Myrvold HE, Wallin L, Julkunen R, Levander K, Hatlebakk JG, Liedman B, Lamm M, Malm A, Walan A, Nordic Gerd Study Group: Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial. Aliment Pharmacol Ther 2006;23:639–647.
86.
Malfertheiner P, Megraud F, O’Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ, European HelicobacterStudy Group (EHSG): Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772–781.
87.
Canani RB, Terrin G: Gastric acidity inhibitors and the risk of intestinal infections. Curr Opin Gastroenterol 2010;26:31–35.
88.
Canani RB, Cirillo P, Roggero P, Romano C, Malamisura B, Terrin G, Passariello A, Manguso F, Morelli L, Guarino A, Working Group on Intestinal Infections of the Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition (SIGENP): Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics 2006;117:e817–e820.
89.
Johnstone J, Nerenberg K, Loeb M: Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. Aliment Pharmacol Ther 2010;31:1165–1177.
90.
Meuwissen SG, Craanen ME, Kuipers EJ: Gastric mucosal morphological consequences of acid suppression: a balanced view. Best Pract Res Clin Gastroenterol 2001;15:497–510.
91.
Kaye JA, Jick H: Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 2008;28:951–959.
92.
Brewster UC, Perazella MA: Proton pump inhibitors and the kidney: critical review. Clin Nephrol 2007;68:65–72.
93.
Merwat SN, Spechler SJ: Might the use of acid-suppressive medications predispose to the development of eosinophilic esophagitis? Am J Gastroenterol 2009;104:1897–1902.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.